Exactly right. Bedgie is suffering from the classic appeal-to-authority fallacy. I mean, at least use a Go8 professor if you're going to play that card. We should just trust this Prof even though he is being paid by Recce, funded by Recce, and has a vested interest in the investigations continuing. We have things like control arms and peer review for these exact reasons, things that Recce have never ever done or used.
And once again... the outcome was to "Evaluate the efficacy of RECCE topical gel on ABSSSI". So just by evaluating the efficacy, they have "met" their "endpoint".
This is an example of what Recce should be defining and reporting on:
“The proportion of patients who achieve clinical cure (defined as improvement from "moderate or severe infection" at baseline to "no infection or mild infection" on the Lipsky scale) by day 28 post-treatment, without requiring further antibiotic therapy."
RCE Price at posting:
40.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)